Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate

BACKGROUND AND OBJECTIVES: Dimethyl fumarate (DMF), an oral disease-modifying therapy with an established benefit and well-described safety profile, is among the most commonly used therapies for relapsing forms of multiple sclerosis. As of 31 December 2021, >560,000 patients have been treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyons, Jennifer, Hughes, Richard, McCarthy, Kerry, Everage, Nicholas, Kapadia, Shivani, Miller, Catherine, Singhal, Priya, Smirnakis, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661630/
https://www.ncbi.nlm.nih.gov/pubmed/36387034
http://dx.doi.org/10.1177/20552173221132469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661630/
https://www.ncbi.nlm.nih.gov/pubmed/36387034
http://dx.doi.org/10.1177/20552173221132469

Ejemplares similares